0001178913-14-002976.txt : 20140918 0001178913-14-002976.hdr.sgml : 20140918 20140918175919 ACCESSION NUMBER: 0001178913-14-002976 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140916 FILED AS OF DATE: 20140918 DATE AS OF CHANGE: 20140918 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Protalix BioTherapeutics, Inc. CENTRAL INDEX KEY: 0001006281 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 650643773 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 SNUNIT ST STREET 2: SCIENCE PARK, POB 455 CITY: CARMIEL STATE: L3 ZIP: 20100 BUSINESS PHONE: 972-4-988-9488 MAIL ADDRESS: STREET 1: 2 SNUNIT ST STREET 2: SCIENCE PARK, POB 455 CITY: CARMIEL STATE: L3 ZIP: 20100 FORMER COMPANY: FORMER CONFORMED NAME: ORTHODONTIX INC DATE OF NAME CHANGE: 19980422 FORMER COMPANY: FORMER CONFORMED NAME: EMBASSY ACQUISITION CORP DATE OF NAME CHANGE: 19960124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bio-Cell Ltd CENTRAL INDEX KEY: 0001385114 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33357 FILM NUMBER: 141110691 BUSINESS ADDRESS: STREET 1: MOSHE AVIV TOWER STREET 2: 7 ZABOTINSKY STREET CITY: RAMAT GAN STATE: L3 ZIP: 52520 BUSINESS PHONE: 972-3-611-4514 MAIL ADDRESS: STREET 1: MOSHE AVIV TOWER STREET 2: 7 ZABOTINSKY STREET CITY: RAMAT GAN STATE: L3 ZIP: 52520 4 1 zk1415562.xml OWNERSHIP DOCUMENT X0306 4 2014-09-16 1 0001006281 Protalix BioTherapeutics, Inc. PLX 0001385114 Bio-Cell Ltd MOSHE AVIV TOWER 7 ZABOTINSKY STREET RAMAT GAN L3 52529 ISRAEL 0 0 1 0 Common Stock 2014-09-16 4 J 0 8556371 D 1509948 I By Trust The reporting person, Biocell Ltd., distributed 8,554,988 shares of common stock of Protalix BioTherapeutics, Inc., in a dividend to its shareholders on a pro rata basis based on their respective percentage interests in Biocell Ltd. Biocell Ltd. is an Israeli public company traded on the Tel Aviv Stock Exchange Ltd. The shares were transferred to the Biocell Ltd. shareholders on a pro rata basis based on their respective percentage interests in Biocell Ltd. No consideration was paid in connection with the transfer. Substantially all of the shares of Protalix BioTherapeutics, Inc. common stock held by Biocell Ltd. following the dividend reported in this Form 4 are held in a trust for the benefit of Biocell Ltd. /s/ Zeev Bronfeld 2014-09-18